Gapping up
In reaction to earnings/guidance:
- MTG +4.2%, MTB +3.6%, EGBN +0.5%
M&A news:
- TA +9.1% (to acquire travel center properties from HPT and amend existing leases)
- CARS +7.7% (announces review of strategic alternatives in pursuit of enhancement of shareholder value)
- ADM +0.9% (to acquire Gleadell Agriculture Ltd and Dunns Ltd, combining existing UK origination entities to create ADM)
Other news:
- LPCN +68.6% (Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results)
- ADMP +12.5% (Adamis Pharma's partner Sandoz launched SYMJEPI epinephrine to the U.S. market)
- PCG +6% (ongoing volatility; BlueMountain Capital delivers letter to the Board challenging their plans to file for Chapter 11)
- MRTX +3.2% (prices 1,612,903 shares of its common stock at a price to the public of $62.00 per share)
- MNKD +1.5% (announces direct purchase insulin program for Afrezza)
- SPPI +1% (to sell portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma for $160 mln up-front cash payment and up to $140 mln in milestones)
Analyst comments:
- FOLD +3.1% (upgraded to Buy at Citigroup)
- CDXS +2.1% (upgraded to Outperform from Neutral at First Analysis Sec)
- ARRY +1.1% (initiated with a Outperform at Leerink Partners)